Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5615_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
19 Мб
Скачать
PEGylation ofTherapeutic Proteins andPeptides
NatashaAkojwar, AnkitMishra , PranaliMishra , MuktikaTekade, ShubhamRamdasMule, andRakeshKumarTekade
Abstract
PEGylation refers to the technique of modifying protein and peptide drugs with
PEG, which offers numerous advantages over their unmodied counterparts in
terms of physicochemical properties and therapeutic efcacy. This book chapter
N. Akojwar Department of Pharmaceutical Sciences, Rashtrasant Tukdoji Maharaj Nagpur University, Nagpur, MS, India
A. Mishra (*) Department of Pharmaceutics, VNS Group of Institutions, Faculty of Pharmacy, Bhopal, MP, India
P. Mishra Department of Pharmaceutics, VNS Group of Institutions, Faculty of Pharmacy, Bhopal, MP, India
Swami Vivekanand College of Pharmacy, Bhopal, MP, India
M. Tekade School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshila Campus, Indore, Madhya Pradesh, India
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
S. R. Mule National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar, Gujarat, India
R. K. Tekade National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air force station, Gandhinagar, Gujarat, India
11
317
318
N. Akojwar et al.
aims to equip the readers with detailed insights into objectives, methods, and end
applications of PEGylation. The chemistry-related aspects of PEGylation, with
special emphasis on the site of PEGylation, is the central theme of this piece of
literature. Various critical factors affecting the process of PEGylation and its out-
comes, such as the structure of PEG and size of PEG, have been emphasized in
this manuscript. The applications of PEGylation in active and passive targeting
and various FDA-approved PEGylated products are thoroughly discussed.
Keywords
PEG · PEGylation · Proteins · Peptides · PK proling

11.1 Introduction

The advancements in the modern technologies of production, modication, and analytical advancements have helped in the development of protein and peptide drugs (PPDs) signicantly during the past 10 years (Henninot etal. 2018). Countless therapeutic applications for natural and synthetic peptides have been discovered and explored. The application of PPDs as therapeutics has been viewed as an appealing strategy to tackle numerous diseases since the isolation of insulin in 1922 (Bliss
1982). Recent advancements in biotechnology and pharmaceutical sciences, espe-
cially recombinant technology, have made it feasible to develop PPDs commercially as promising therapeutics (Gupta etal. 2016; Seif etal. 2017). Protein and peptide medications are intriguing biological molecules in drug research because they offer great efcacy, minimal toxicity, and strong specicity compared to conventional chemically manufactured pharmaceuticals (Dimitrov 2012).
By far, the FDA has approved more than 240 PPDs. Other potential therapeutic PPD candidates undergo clinical trials (Chen etal. 2022). PPDs have been synthe­sized and modied utilizing both biological and chemical techniques. Although pro­tein and peptide medications offer unrivaled benets in treating disease conditions at the cellular and extracellular levels, they are not the ideal treatment choice owing to their molecular makeup. These macro-molecules are difcult to administer because of their large size, complex structure, hydrophilicity, immunogenicity, and susceptibility to enzymatic cleavage, leading to shorter half-life necessitating fre­quent administration (Joseph etal. 2017).
Researchers attempt various approaches to recongure these PPDs to address the above issues, and many of these techniques can drastically enhance their sta­bility and safety and improve their pharmacokinetic prole while lowering the dose and frequency of administration. The novel design and delivery technologies assisted in overcoming the inherent limitations of PPDs, permitting the continu­ous expansion of this industry. The following section will review PEGylation as one of the strategies researchers employ to combat the shortcomings of protein and peptide drugs.
11 PEGylation ofTherapeutic Proteins andPeptides
319
11.1.1 Clinical andResearch Status ofPPDs
From the 1980s to the 1990s, peptide products with 2–10 amino acids comprise a large portion of the amino acid composition of polypeptide drugs. However, as pep­tide synthesis and purication technology have advanced in the twenty-rst century, polypeptide products with more than ten amino acids have gradually emerged, and the myriad of polypeptide drugs has expanded (Lau and Dunn 2018). According to global industry research on peptide treatments, peptide medicine sales surpassed 70 billion USD in 2019; this research forecasted a compound annual growth rate (CAGR) reach­ing 9.1% from 2016 to 2024. Over 100 peptide therapeutics have entered clinical tri­als, over 400 peptide-based drugs are in the pre-clinical research phase, and more than 70 peptide drug types have been certied globally for commercialization (Lee etal.
2019). On studying the intended uses of these licensed peptide medications, it appears
that the most frequently targeted disease groups are cancer and metabolic disorders. It can be said that the robust expansion of this industry is probably due to the anticipated rise in the prevalence of malignancies and metabolic diseases (Li etal. 2021; Cheetham etal. 2016). Liraglutide (Victoza) and glucagon-like peptide 1 (GLP-1) are top-selling peptide medications for metabolic disorders, total sales of at least two billion USD annually. Over four billion USD in sales were also attributed to well-known peptide medications like leuprolide (Lupron), gosarelin (Zoladex), and somatostatin analogs like octreotide and lanreotide (Ibeanu etal. 2020).
Correspondingly, there is an increase in the variety of protein and peptide therapeutic molecular targets. G-protein-coupled receptors (GPCRs) are the most prominent extra­cellular targets, preceded by the natriuretic peptide receptor and cytokine receptor fam­ily. These three receptor families are the primary targets of 70–90% of the peptide medicines tested in clinical studies (Sriram and Insel 2018; Davenport etal. 2020). Thus, drug research currently focuses on identifying the role of proteins and peptides in the etiology of a disease; these proteins include enzymes, viral proteins, receptors, and channel molecules. Therefore, conducting an in-depth analysis of protein and peptide therapeutic targets is crucial for developing these novel medicines (Lagassé etal. 2017).

11.1.2 Factors Influencing PPDs’ Short-Term Efficiency

Major drawbacks of these peptide and protein therapies include limited bioavailabil­ity and higher metabolic sensitivity. The GI tract’s digestion of peptides and their failure to cross the epithelium limits their oral bioavailability (Alqahtani etal. 2019). These PPDs frequently have high molecular weights (MWs), minimal lipophilicity, and charged moiety within their structure, all hindering absorption (Han etal. 2019). These properties cause most orally given peptides to have low bioavailability (2%) and brief half-lives (30min). The problem of absorption is resolved by intravenous (IV) or subcutaneous (SC) delivery of these therapeutic agents, but other factors, such as systemic proteolytic enzymes, rapid clearance, opsonization, structural rear­rangements, separation of subunit protein molecules, complex formation with blood components, and destabilization of susceptible side-groups, limit the bioavailability of these therapeutics (Craik etal. 2013). Another challenge is that the PPDs are dif­cult to manufacture and store because of poor stability (Bruno etal. 2013).
320
Fig. 11.1 Various factors affecting the half-lives of protein and peptide drugs
N. Akojwar et al.
Furthermore, every protein therapy has the potential to cause immunogenicity complications in patients, and antibody formation is one such concern that poses serious safety issues and lowers the efcacy of PPDs (Szlachcic etal. 2011; Fu etal.
2020). Above all, the short half-lives of the PPDs limit their potential application.
The most common causes of the short half-life of PPDs are depicted in Fig.11.1. The hepatic and renal tissues and bloodstream all contain signicant numbers of peptidases and proteases, which cause the peptide or protein to be swiftly broken down by the enzyme’s function. Renal ltration, on the other hand, leads to quick elimination of PPDs with low molecular weights. Liver metabolism is another fac­tor inuencing the half-life of PPDs. The particular sequence of amino acids of a polypeptide chain also signicantly impacts their hepatocyte intake and the rate at which the liver metabolizes them; this uptake is a crucial step as the liver largely metabolizes them. Various drug delivery systems and administration routes may impact the drugs’ pharmacokinetics (ADME) and metabolic processes, ultimately affecting the half-life of PPDs (Cao etal. 2020).

11.2 What Is PEGylation?

PEGylation is the non-covalent or covalent modication of other molecules utiliz­ing polyethylene-glycol (PEG). This PEGylation produces interesting outcomes in PPDs. It has produced a revolutionary product line that has already hit the market, and others will be accessible soon. PEGylation enables the therapeutic use of PPDs with poor pharmacokinetics to be clinically applicable (Pasut and Veronese 2006).
11 PEGylation ofTherapeutic Proteins andPeptides
321
Frank Davis’s laboratories conducted early research on PEGylated proteins and enzymes in the late 1970s. Researchers today established the groundwork for pro­tein PEGylation as a targeted delivery mechanism. In a series of experiments by Davis etal., cyanuric chloride was used to couple a methoxy-PEG to the amino acids in proteins. Their research showed that PEGylated proteins exhibited lower immunogenicity and longer circulatory half-lives. PEGylation has been a widely used technique in targeted drug delivery systems due to the recently discovered use of proteins in therapeutics (Dozier and Distefano 2015).
In PEGylation, proteins, peptides, antibodies, and vesicles are biochemically modied using PEG to give them numerous desired qualities that are useful for cell genetic modication or therapy. Nevertheless, PEGylation of proteins is a compli­cated procedure that can be accomplished using a variety of approaches (enzymatic, entrapping, physical, and chemical methods), depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Several PEGylated medications are used for conditions such as anemia, kidney dysfunction, multiple sclerosis, hemophilia, and malignancies (Awwad etal. 2018).
The increased hydrodynamic volume of the PEG–protein conjugate, which is a result of the potential of PEG to co-ordinate water molecules as well as from the exibility of the PEG chain, can be used to explain why the physicochemical prop­erties of a protein have signicantly improved after coupling of PEG to a protein. As a result, the PEG protein conjugate has an apparent molecular weight that is roughly ve to ten times more than the protein’s nominal molecular weight (Gupta etal.
2019). Besides, PEG chains can wrap around a protein to cloak and protect it from
exposure to the environment. Still, they can also affect how the protein interacts with other proteins, which affects how well the protein performs its biological func­tion. Typically, in biological systems, these adverse impacts are counterbalanced by important positive consequences they offer, viz., enhanced blood circulation, increased drug bioavailability by evading the digestive system, reduced toxicity, decreased immunogenicity, and enhanced passive drug delivery (Jevsevar et al.
2010). Figure11.2 gives detailed insights into the process of PEGylation.
11.2.1 Ideal Properties ofPEG
PEG are inert, long-chain amphiphilic molecules synthesized by connecting ethylene oxide repeating units. Many possible PEG molecules can be made in various arrange­ments, such as linear or branched architectures, and with different molecular weights. The immunologic, pharmacokinetic, and pharmacodynamic characteristics of a target protein are altered by PEGylation, which can expand the protein’s possible applica­tions (Harris etal. 2001). Although PEG is typically considered a non- biodegradable polymer, certain studies have shown that it can be oxidatively broken down by various enzymes, including alcohol and aldehyde dehydrogenases and CYP450-dependent oxidases (Beranová etal. 1990). Reports presented that Alcohol dehydrogenases con­vert PEG chains under 400Da invivo into harmful metabolites. The elimination of longer PEG chains, utilized for PEGylate proteins, depends on their molecular mass
322
Fig. 11.2 Overview of the process of PEGylation
N. Akojwar et al.
and is not susceptible to metabolism. Renal ltration eliminates PEG and PEG–pro­tein complexes with PEGs smaller than 20kDa. In contrast, protein complexes with bigger PEG molecules are eliminated from the body through different pathways, such as hepatic uptake, immune system interaction, and proteolytic metabolism of the pro­tein component of the conjugate (Caliceti and Veronese 2003).
PEG has a longstanding experience of being a non-toxic, non-immunogenic, water-loving, neutral, and non-degradable polymer and has been given the “gener­ally regarded as safe” certication by the US FDA (Alconcel etal. 2011). PEGs and PEG reagents with wide polydispersity have been utilized; today, the acceptable standard for PEG reagents up to 30 kDa is polydispersity indices of about 1.05 (Wang etal. 2020a). A polydispersity around 1.1 might be appropriate for higher molecular weight forms, but the current trend is to use PEGs with narrower distribu­tions. High doses of PEG as an intravenous therapeutic agent have been demon­strated to cause dose-dependent and molecular mass-dependent systemic immune toxic reactions. PEGylated therapies utilize 10,000 to 1000-fold lower amounts of PEG. Hence, therapeutic doses of PEGylated medications are generally signi­cantly lower than those needed to cause PEG toxicity (Webster etal. 2009).
In toxicity studies, it has been shown that extremely high dosages of PEG–pro­tein conjugates can cause nephron vacuolization, which is not accompanied by functional problems and goes away after the therapy (Rudmann etal. 2013). As a result, PEG–protein conjugates continue to be considered non-toxic, safe, and immunologically harmless. It has also been shown that the attachment of longer, branching PEGs is preferable to shorter, linear PEGs for reducing possible protein immunogenicity. PEG’s minimal immunogenicity and the comparatively low doses
11 PEGylation ofTherapeutic Proteins andPeptides
323
of PEG-conjugates greatly limit the chance of an immunogenic reaction (Qi and Chilkoti 2015).
11.2.2 Advantages ofPEGylation
The PPD’s physicochemical characteristics are changed due to PEGylation, includ­ing its conformational, steric impediment, electrostatic interaction capabilities, and lipophilicity. The improvement in the therapeutic efciency that PEGylation offers because of the several advantages over non-PEGylated products is summed up in this section. Figure11.3 enlists the benets of PEGylation. PEGylation expands the size and molecular mass of PPDs, boosts their water solubility, and improves their phar­macokinetics and pharmacodynamics. PEG polymer interacts with two or more water molecules for every ethylene glycol subunit when coupled to a protein (Delgado etal. 1992). This property produces a bulky hydrophilic shielding that effectively hides the conjugated protein from immune detection and enzymatic breakdown.
Additionally, the conjugated protein is ve to ten times bigger and more soluble than an equivalent soluble protein of the same mass. The shield produced by the PEG moiety and linked water molecules signicantly reduces renal clearance (Milla etal. 2012). This last characteristic seems to be especially benecial for smaller proteins and peptides, which the kidneys lter quickly. To lengthen the body’s resi­dence period, PEGylation with a PEG mass of 40–50kDa can be accomplished by conjugating either a single large PEG molecule or numerous smaller PEG mole­cules (Vargason etal. 2021).
PEGylation increases the plasma half-life of proteins and prevents phagocytic system clearance by producing a steric obstacle to opsonization. Proteases are hin­dered by PEG, which increases the proteins’ resistance to proteolytic breakdown. PEGylation can maintain the protein structure and function this way (Veronese
2001). Additionally, PEGylation can mask antigenic regions of foreign proteins,
preventing the development of antibodies directed against the same, thereby lower­ing their immunogenicity (Knop etal. 2010). Adenosine deaminase became the rst PEGylated PPD commercialized and licensed by the FDA to manage immunode­ciency illnesses in 1990. Ever since, numerous conjugates have received approval
Fig. 11.3 Advantages of PEGylation of proteins and peptides
324
N. Akojwar et al.
and gone on the market, including epotein protein for treating renal failure, PEGylated interferon for treating hepatitis C, and granulated stimulating factor for treating neutropenia (Villegas etal. 2018).
Shorter half-lives invivo, which lead to much lower potency as demonstrated invitro, limit the biological agent’s incredible potential. These frequently needed short-acting therapeutic drugs, specically for chronic illnesses, can limit their application in the clinic. To enable better biological treatments, half-life augmenta­tion approaches are now available in clinical settings (Swierczewska etal. 2015). The most well-established half-life extension technique today is PEGylation, which has been safe in humans for over two decades. It also helps reduce the dose and frequency of application, enhancing patient compliance. Nevertheless, it will be among the most cutting-edge systems used during the next 20years.
11.2.3 Generations ofPEGylation Process
The key trait of low molecular weight linear PEGs denes the rst-generation PEG­conjugated therapeutic proteins. The activation of PEG is required before it is con­jugated to a protein. This activation is done utilizing a functional group located on one of its terminal sides appropriate for interaction with an available active site on the protein (typically the amino groups). This activation could be achieved by react­ing the PEG with a proper initiator or termination reagent (Swierczewska etal.
2015). Because of the availability to create reactive PEGs that stop the synthesis of
cross-linked polypeptides, monomethoxy PEG (mPEG) is more appropriate for conjugating proteins (Monfardini et al. 1995). It is hypothesized that the PEG’s amphiphilic property, ability to bind to water molecules, and exibility of the back­bone chain are related to its capacity to induce precipitation of proteins, reduce immunogenicity and antigenicity, keep proteins and cells away from surfaces, and prevent degradation by enzyme activity or mammalian cells.
Furthermore, irreversible conjugation is necessary to achieve the primary goal of rst-generation PEGylation. Due to the removal of the PEG coating, the method’s wide­spread use is restricted. Regulators approved several rst-generation pegylated medica­tions despite these restrictions. Pegaspargase (Oncaspar), a pegylated form of the enzyme asparaginase employed for leukemia, and pegademase (Adagen), a pegylated derivative of the enzyme adenosine deaminase for the treatment of severe combined immunodeciency disease (SCID), are still in use today (Harris and Chess 2003).
The second generation of PEGylation has developed from the rst generation, and it uses a site-specic PEGylation technique to strengthen the specicity between PEG with different protein moieties. Chemically stable bonds are indeed site­specically created during covalent PEGylation, which is a most desirable and potentially economical method. Some techniques used to carry out site-specic PEGylation include thiol, N-terminal, and histidine markers. Constantly reversible conjugation, which does not impede conjugate activity, is the primary method of site-specic PEGylation (Belén etal. 2019). As a result, the conjugates could be liberated per a predetermined period attributable to the use of the cleavable link­ages, which enable temporary anchoring of PEG molecules. However, a covalent
11 PEGylation ofTherapeutic Proteins andPeptides
325
approach has signicant drawbacks; it may not always be practical and could take the longest to develop.
Like random PEGylation, multiple target-specic sites in the molecule may also form PEGylated species with different degrees of modication and isomerism posi­tions (Zuma etal. 2022). Creating larger PEG polymers is a general objective of second-generation PEGylation techniques to enhance the pharmacokinetic and pharmacodynamic consequences observed following relatively low molecular mass PEGs. Some of the changes are signicant, such as the PEGylation of interleukin-6 (IL-6), which caused a 100-fold increase in half-life and a 500-fold increase in thrombopoietin activity (Harris etal. 2001).
Using branching structures instead of the only linear structures present in rst­generation PEGs is another advancement in second-generation PEG polymers. There have been developed branched PEGs with signicantly higher molecular weights (up to 60kDa or above) than the 12kDa or fewer observed in rst- generation PEGs. A branching PEG is much larger than a linear PEG with the same molecular mass (Fee 2007).
Additionally, branched PEGs are more effective at shielding the connected poly­peptide drug again from immune cells and digestive enzymes, lowering its antigenic­ity and reducing the probability that it will be destroyed. To attain better potency and a circulation half-life focused on fast-acting, site-specic, and lower doses, third-gen­eration PEGylation is being developed (Kursa etal. 2003). With an aim to establish longer-acting therapeutics, third-generation PEGylation seeks to reduce the struggle to nd a balance between efciency and circulatory half-life. Releasable PEG conju­gates, a prodrug strategy invented by Enzon Pharmaceuticals, are one method. After being administered invivo, the medication can be converted to its active form owing to specially designed linkers between PPD active molecules and PEG.Another strat­egy to reduce the API’s steric barrier is constructing modiable PEGylation regions on proteins using technologies like Ambrx’s ReCODE and EuCODE to support thera­peutic candidates with problematic PK characteristics (Manandhar etal. 2021).
11.3 Chemistry ofPEGylation
Proteins and appropriately activated PEGylation reagents often interact chemically to PEGylate proteins. There are many chemical groups on the side chains of amino acids that might feasibly be used for the interaction with PEG, including disulde (-S-S-) bonds, -NH2, -NH-, -COOH, -OH, and -SH groups. The location of attach­ment upon the protein, the nature of bonding, the size and form of the linker, and the PEG reagent are all factors that must be considered when discussing PEGylation, particularly when considering their modied properties (Zalipsky 1995).

11.3.1 Random PEGylation

In the 1970s, the historical background of “random” PEGylation reagents com­menced with PEG-chlorotriazine. It proceeded with PEG-benzotriazole carbonate,
326
N. Akojwar et al.
PEG-tosylate, PEG-nitrophenyl carbonate, PEG-carbonyl imidazole, succinimidyl succinate (SS-PEG), as well as succinimidyl carbonate PEG reagents (SC-PEGs). Although SS-PEG reagents form strong amide bonds with protein, the subsequent PEG-protein adducts are vulnerable to hydrolysis because of an additional ester link­age in the polymer’s backbone. In addition to reacting with lysine residues, SC-PEG reagents also react with histidine residues, forming urethane linkages, which lead to hydrolytically weak bonds (Zalipsky etal. 1992). The weak connection could be advantageous when designing control release or prodrug compositions, but if conju­gation instability is not desired, it could be a severe drawback (Warren etal. 2012).
Looking back at the development of PEGylation, it is apparent that, until recently, the preponderance of PEGylation reagents primarily targeted the amino groups on side chains of lysine residues in proteins, which is considered random PEGylation. Lysines are relatively numerous, polar amino acid residues typically found on the surface of proteins, making them susceptible to chemical interactions with PEG reagents. As a result, these reactions proceed rapidly and produce complex mixes of conjugates that vary in the quantity and location of the attached PEG chains (Cheng etal. 2019). These reactions are not conned to the amino groups of lysine residues; they also somewhat react with certain other protein nucleophiles, such as the side chains of serine, threonine, and tyrosine cysteine residues, the N-terminal amino groups and the imidazolyl nitrogens of histidine residues. Although the pH of the medium can inuence the reaction to some degree, these conjugation processes typically result in complex PEGylation mixes (Maiser et al. 2014). Also, rst­generation high molecular weight, pure monofunctional PEG reagents are challeng­ing to construct and ineffective for protein conjugation because they have a 15% maximum diol concentration (Zhang etal. 2007).

11.3.2 Site-Specific PEGylation

The issues of diol contaminants, connement to low-molecular-weight mPEG, instability of links, side-reactions, and lack of substitution selectivity have been avoided by site-specic PEGylation chemistry (Xu etal. 2021). N-terminal, serine, threonine, tryptophan, and cysteine PEGylations are examples of traditional, well­known methods for site-specic PEGylation reactions discussed in the following section.
11.3.2.1 Amine Conjugation
mPEG-propionaldehyde is one of the earliest instances of second-generation chem­istry. Given the PEG acetaldehyde’s susceptibility to dimerization, mPEG­propionaldehyde is simpler to manufacture and employ. Because the N-terminal alpha-amine has a lower pKa than other nucleophiles, mPEG-propionaldehyde is mainly selected for it under acidic circumstances (about pH5). The nucleophilicity of every amino acid residue plays a critical role in attaching electrophilic PEG to amino acid residue on protein. Only after the pH of the solution containing protein is close to or higher than the residue’s pKa will a nucleophilic attack occur. As a result, each residue’s reactivity is also inuenced by its nearby amino acid residues. The